Two UK directors of Vertex Pharmaceuticals made more than 15 million pounds from share options in 2017, The Guardian reported Tuesday.
The news comes as the drugmaker has reached a stalemate in negotiations with NHS over the price of the cystic fibrosis drug Orkambi.
NHS England has offered to pay 500 million pounds over five years to cover the drug in exchange for price cuts, with Vertex declining the deal.
In addition to the share options, Simon Lem and Simon Bedson also received 1.1 million pounds in compensation.
Meanwhile, Vertex CEO Jeff Leiden has also received criticism in the US over his total compensation of $78.5 million in 2017.
Rebecca Hunt, Vertex's international vice-president of corporate affairs, noted that the company has invested more than $11.3 billion in R&D since 2017, adding "in the context of these huge investments, executive pay is not a significant factor in the cost of the medicines."
To read more NewsPoints articles, click here.